Download PDF
Thromb Haemost 2008; 99(01): 4-13
DOI: 10.1160/TH07-08-0513
Review Article
Schattauer GmbH

Idiopathic thrombocytopenic purpura: Current concepts in pathophysiology and management

Roberto Stasi
1   Department of Medical Sciences, Ospedale „Regina Apostolorum“, Albano Laziale, Italy
,
Maria Laura Evangelista
1   Department of Medical Sciences, Ospedale „Regina Apostolorum“, Albano Laziale, Italy
,
Elisa Stipa
2   Division of Hematology, Ospedale S. Eugenio, Rome, Italy
,
Francesco Buccisano
3   Department of Hematology, “Tor Vergata” University Hospital, Rome, Italy
,
Adriano Venditti
3   Department of Hematology, “Tor Vergata” University Hospital, Rome, Italy
,
Sergio Amadori
3   Department of Hematology, “Tor Vergata” University Hospital, Rome, Italy
› Author Affiliations
Further Information

Publication History

Received: 22 August 2007

Accepted after major revision: 10 October 2007

Publication Date:
24 November 2017 (online)

Also available at
   Permissions and Reprints

Summary

Idiopathic thrombocytopenic purpura (ITP) is characterized by a low platelet count, which is the result of both increased platelet destruction and insufficient platelet production. Although the development of autoantibodies against platelet glycoproteins remains central in the pathophysiology of ITP, several abnormalities involving the cellular mechanisms of immune modulation have been identified. Conventional treatments for ITP aim at reducing platelet destruction, either by immunosuppression or splenectomy. Two new thrombopoietic agents, AMG 531 and eltrombopag, have been used in clinical trials to stimulate platelet production in ITP patients not responsive to standard treatments. These new molecules bear no structural resemblance to thrombopoietin, but still bind and activate the thrombopoietin receptor. This review will focus on the pathophysiology and treatment of ITP in adults, highlighting recent advances in both fields.

Keywords

Thrombocytopenia - platelet immunology - immunity
 

  • References

  • 1 George JN, Woolf SH, Raskob GE. et al. Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology. Blood 1996; 88: 3-40.
    PubMedGoogle Scholar
  • 2 Frederiksen H, Schmidt K. The incidence of idiopathic thrombocytopenic purpura in adults increases with age. Blood 1999; 94: 909-913.
    PubMedGoogle Scholar
  • 3 Neylon AJ, Saunders PW, Howard MR. et al. Clinically significant newly presenting autoimmune thrombocytopenic purpura in adults: a prospective study of a population-based cohort of 245 patients. Br J Haematol 2003; 122: 966-974.
    CrossrefPubMedGoogle Scholar
  • 4 Stasi R, Amadori S, Osborn J. et al. Long-term outcome of otherwise healthy individuals with incidentally discovered borderline thrombocytopenia. PLoS Med 2006; 3: e24.
    CrossrefPubMedGoogle Scholar
  • 5 Cohen YC, Djulbegovic B, Shamai-Lubovitz O. et al. The bleeding risk and natural history of idiopathic thrombocytopenic purpura in patients with persistent low platelet counts. Arch Int Med 2000; 160: 1630-1638.
    CrossrefPubMedGoogle Scholar
  • 6 Portielje JE, Westendorp RG, Kluin-Nelemans HC. et al. Morbidity and mortality in adults with idiopathic thrombocytopenic purpura. Blood 2001; 97: 2549-2554.
    CrossrefPubMedGoogle Scholar
  • 7 Stasi R, Provan D. Management of immune thrombocytopenic purpura in adults. Mayo Clinic Proc 2004; 79: 504-522.
    CrossrefPubMedGoogle Scholar
  • 8 Cines DB, Bussel JB. How I treat idiopathic thrombocytopenic purpura (ITP). Blood 2005; 106: 2244-2251.
    CrossrefPubMedGoogle Scholar
  • 9 George JN. Management of patients with refractory immune thrombocytopenic purpura. J Thromb Haemost 2006; 4: 1664-1672.
    CrossrefPubMedGoogle Scholar
  • 10 Bussel J. Treatment of immune thrombocytopenic purpura in adults. Sem Hematol 2006; 43: S3-10 discussion S18-19.
    PubMedGoogle Scholar
  • 11 Beardsley DS. ITP in the 21st century. Hematology / the Education Program of the American Society of Hematology American Society of Hematology. 2006: 402-407.
    PubMedGoogle Scholar
  • 12 Harrington WJ, Minnich V, Hollingsworth JW. et al. Demonstration of a thrombocytopenic factor in the blood of patients with thrombocytopenic purpura. J Lab Clin Med 1951; 38: 1-10.
    PubMedGoogle Scholar
  • 13 Shulman NR, Marder VJ, Weinrach RS. Similarities between known antiplatelet antibodies and the factor responsible for thrombocytopenia in idiopathic purpura. Physiologic, serologic and isotopic studies. Ann NY Acad Sci 1965; 124: 499-542.
    PubMedGoogle Scholar
  • 14 van Leeuwen EF, van der Ven JT, Engelfriet CP. et al. Specificity of autoantibodies in autoimmune thrombocytopenia. Blood 1982; 59: 23-26.
    PubMedGoogle Scholar
  • 15 McMillan R, Wang L, Tani P. Prospective evaluation of the immunobead assay for the diagnosis of adult chronic immune thrombocytopenic purpura (ITP). J Thromb Haemost 2003; 1: 485-491.
    CrossrefPubMedGoogle Scholar
  • 16 Brighton TA, Evans S, Castaldi PA. et al. Prospective evaluation of the clinical usefulness of an antigen-specific assay (MAIPA) in idiopathic thrombocytopenic purpura and other immune thrombocytopenias. Blood 1996; 88: 194-201.
    PubMedGoogle Scholar
  • 17 Stockelberg D, Hou M, Jacobsson S. et al. Detection of platelet antibodies in chronic idiopathic thrombocytopenic purpura (ITP). A comparative study using flow cytometry, a whole platelet ELISA, and an antigen capture ELISA. Eur J Haematol 1996; 56: 72-77.
    PubMedGoogle Scholar
  • 18 McMillan R, Lopez-Dee J, Bowditch R. Clonal restriction of platelet-associated anti-GPIIb/IIIa autoantibodies in patients with chronic ITP. Thromb Haemost 2001; 85: 821-823.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 19 Fischer P, Jendreyko N, Hoffmann M. et al. Platelet-reactive IgG antibodies cloned by phage display and panning with IVIG from three patients with autoimmune thrombocytopenia. Br J Haematol 1999; 105: 626-640.
    CrossrefPubMedGoogle Scholar
  • 20 Roark JH, Bussel JB, Cines DB. et al. Genetic analysis of autoantibodies in idiopathic thrombocytopenic purpura reveals evidence of clonal expansion and somatic mutation. Blood 2002; 100: 1388-1398.
    PubMedGoogle Scholar
  • 21 Semple JW. Immune pathophysiology of autoimmune thrombocytopenic purpura. Blood Rev 2002; 16: 9-12.
    CrossrefPubMedGoogle Scholar
  • 22 Kuwana M, Kaburaki J, Ikeda Y. Autoreactive T cells to platelet GPIIb-IIIa in immune thrombocytopenic purpura. Role in production of anti-platelet autoantibody. J Clin Invest 1998; 102: 1393-1402.
    PubMedGoogle Scholar
  • 23 Kuwana M, Kaburaki J, Kitasato H. et al. Immunodominant epitopes on glycoprotein IIb-IIIa recognized by autoreactive T cells in patients with immune thrombocytopenic purpura. Blood 2001; 98: 130-139.
    CrossrefPubMedGoogle Scholar
  • 24 Zhou B, Zhao H, Yang RC. et al. Multi-dysfunctional pathophysiology in ITP. Crit Rev Oncol Hematol 2005; 54: 107-116.
    CrossrefPubMedGoogle Scholar
  • 25 Semple JW, Milev Y, Cosgrave D. et al. Differences in serum cytokine levels in acute and chronic autoimmune thrombocytopenic purpura: relationship to platelet phenotype and antiplatelet T-cell reactivity. Blood 1996; 87: 4245-4254.
    PubMedGoogle Scholar
  • 26 Fogarty PF, Rick ME, Zeng W. et al. T cell receptor VB repertoire diversity in patients with immune thrombocytopenia following splenectomy. Clin Exp Immunol 2003; 133: 461-466.
    CrossrefPubMedGoogle Scholar
  • 27 Stasi R, Del Poeta G, Stipa E. et al. Response to B-cell depleting therapy with rituximab reverts the abnormalities of T cell subsets in patients with idiopathic thrombocytopenic purpura. Blood. 2007 in press.
    PubMedGoogle Scholar
  • 28 Olsson B, Andersson PO, Jernas M. et al. T-cell-me-diated cytotoxicity toward platelets in chronic idiopathic thrombocytopenic purpura. Nature Med 2003; 9: 1123-1124.
    CrossrefPubMedGoogle Scholar
  • 29 Gruel Y, Boizard B, Daffos F. et al. Determination of platelet antigens and glycoproteins in the human fetus. Blood 1986; 68: 488-492.
    PubMedGoogle Scholar
  • 30 Filion MC, Proulx C, Bradley AJ. et al. Presence in peripheral blood of healthy individuals of autoreactive T cells to a membrane antigen present on bone marrow-derived cells. Blood 1996; 88: 2144-2150.
    PubMedGoogle Scholar
  • 31 Liu B, Zhao H, Poon MC. et al. Abnormality of CD4(+)CD25(+) regulatory T cells in idiopathic thrombocytopenic purpura. Eur J Haematol 2007; 78: 139-143.
    PubMedGoogle Scholar
  • 32 Olsson B, Andersson PO, Jacobsson S. et al. Disturbed apoptosis of T-cells in patients with active idiopathic thrombocytopenic purpura. Thromb Haemost 2005; 93: 139-144.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 33 Takai T. Roles of Fc receptors in autoimmunity. Nat Rev Immunol 2002; 2: 580-592.
    CrossrefPubMedGoogle Scholar
  • 34 Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med 2002; 346: 995-1008.
    CrossrefPubMedGoogle Scholar
  • 35 Henn V, Slupsky JR, Grafe M. et al. CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 1998; 391: 591-594.
    CrossrefPubMedGoogle Scholar
  • 36 Hermann A, Rauch BH, Braun M. et al. Platelet CD40 ligand (CD40L)--subcellular localization, regulation of expression, and inhibition by clopidogrel. Platelets 2001; 12: 74-82.
    CrossrefPubMedGoogle Scholar
  • 37 Solanilla A, Pasquet JM, Viallard JF. et al. Platelet-associated CD154 in immune thrombocytopenic purpura. Blood 2005; 105: 215-218.
    CrossrefPubMedGoogle Scholar
  • 38 Semple JW, Freedman J. Increased antiplatelet T helper lymphocyte reactivity in patients with autoimmune thrombocytopenia. Blood 1991; 78: 2619-2625.
    PubMedGoogle Scholar
  • 39 McMillan R, Longmire RL, Yelenosky R. et al. Immunoglobulin synthesis in vitro by splenic tissue in idiopathic thrombocytopenic purpura. N Engl J Med 1972; 286: 681-684.
    CrossrefPubMedGoogle Scholar
  • 40 Kuwana M, Okazaki Y, Kaburaki J. et al. Spleen is a primary site for activation of platelet-reactive T and B cells in patients with immune thrombocytopenic purpura. J Immunol 2002; 168: 3675-3682.
    CrossrefPubMedGoogle Scholar
  • 41 Siegel RS, Rae JL, Barth S. et al. Platelet survival and turnover: important factors in predicting response to splenectomy in immune thrombocytopenic purpura. Am J Hematol 1989; 30: 206-212.
    CrossrefPubMedGoogle Scholar
  • 42 Louwes H, Zeinali Lathori OA, Vellenga E. et al. Platelet kinetic studies in patients with idiopathic thrombocytopenic purpura. Am J Med 1999; 106: 430-434.
    CrossrefPubMedGoogle Scholar
  • 43 Nimmerjahn F, Ravetch JV. Fcgamma receptors: old friends and new family members. Immunity 2006; 24: 19-28.
    CrossrefPubMedGoogle Scholar
  • 44 Ericson SG, Coleman KD, Wardwell K. et al. Monoclonal antibody 197 (anti-Fc gamma RI) infusion in a patient with immune thrombocytopenia purpura (ITP) results in down-modulation of Fc gamma RI on circulating monocytes. Br J Haematol 1996; 92: 718-724.
    CrossrefPubMedGoogle Scholar
  • 45 Crow AR, Lazarus AH. Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol 2003; 25 (Suppl. 01) S14-18.
    PubMedGoogle Scholar
  • 46 Crow AR, Song S, Siragam V. et al. Mechanisms of action of intravenous immunoglobulin in the treatment of immune thrombocytopenia. Ped Blood Cancer 2006; 47: 710-713.
    CrossrefPubMedGoogle Scholar
  • 47 Webster ML, Sayeh E, Crow M. et al. Relative efficacy of intravenous immunoglobulin G in ameliorating thrombocytopenia induced by antiplatelet GPIIbIIIa versus GPIbalpha antibodies. Blood 2006; 108: 943-946.
    CrossrefPubMedGoogle Scholar
  • 48 Go RS, Johnston KL, Bruden KC. The association between platelet autoantibody specificity and response to intravenous immunoglobulin G in the treatment of patients with immune thrombocytopenia. Haematologica 2007; 92: 283-284.
    CrossrefPubMedGoogle Scholar
  • 49 Heyns AD, Lotter MG, Badenhorst PN. et al. Kinetics and sites of destruction of 111Indium-oxine-labeled platelets in idiopathic thrombocytopenic purpura: a quantitative study. Am J Hematol 1982; 12: 167-177.
    CrossrefPubMedGoogle Scholar
  • 50 Ballem PJ, Segal GM, Stratton JR. et al. Mechanisms of thrombocytopenia in chronic autoimmune thrombocytopenic purpura. Evidence of both impaired platelet production and increased platelet clearance. J Clin Invest 1987; 80: 33-40.
    PubMedGoogle Scholar
  • 51 Hoffman R, Zaknoen S, Yang HH. et al. An antibody cytotoxic to megakaryocyte progenitor cells in a patient with immune thrombocytopenic purpura. N Engl J Med 1985; 312: 1170-1174.
    CrossrefPubMedGoogle Scholar
  • 52 Chang M, Nakagawa PA, Williams SA. et al. Immune thrombocytopenic purpura (ITP) plasma and purified ITP monoclonal autoantibodies inhibit megakaryocytopoiesis in vitro. Blood 2003; 102: 887-895.
    CrossrefPubMedGoogle Scholar
  • 53 Takahashi R, Sekine N, Nakatake T. Influence of monoclonal antiplatelet glycoprotein antibodies on in vitro human megakaryocyte colony formation and proplatelet formation. Blood 1999; 93: 1951-1958.
    PubMedGoogle Scholar
  • 54 Handin RI, Stossel TP. Effect of corticosteroid therapy on the phagocytosis of antibody-coated platelets by human leukocytes. Blood 1978; 51: 771-779.
    PubMedGoogle Scholar
  • 55 Fujisawa K, Tani P, Piro L. et al. The effect of therapy on platelet-associated autoantibody in chronic immune thrombocytopenic purpura. Blood 1993; 81: 2872-2877.
    PubMedGoogle Scholar
  • 56 Kitchens CS, Pendergast JF. Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. Blood 1986; 67: 203-206.
    PubMedGoogle Scholar
  • 57 Cheng Y, Wong RS, Soo YO. et al. Initial treatment of immune thrombocytopenic purpura with high-dose dexamethasone. N Engl J Med 2003; 349: 831-836.
    CrossrefPubMedGoogle Scholar
  • 58 Mazzucconi MG, Fazi P, Bernasconi S. et al. Therapy with high-dose dexamethasone (HD-DXM) in previously untreated patients affected by idiopathic thrombocytopenic purpura: a GIMEMA experience. Blood 2007; 109: 1401-1407.
    CrossrefPubMedGoogle Scholar
  • 59 Lazarus AH, Crow AR. Mechanism of action of IVIG and anti-D in ITP. Transfus Apher Sci 2003; 28: 249-255.
    CrossrefPubMedGoogle Scholar
  • 60 Samuelsson A, Towers TL, Ravetch JV. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science NY 2001; 291: 484-486.
    CrossrefPubMedGoogle Scholar
  • 61 Ott VL, Fong DC, Cambier JC. Fc gamma RIIB as a potential molecular target for intravenous gamma globulin therapy. J Allergy Clin Immunol 2001; 108: S95-98.
    CrossrefPubMedGoogle Scholar
  • 62 Crow AR, Song S, Freedman J. et al. IVIg-mediated amelioration of murine ITP via FcgammaRIIB is independent of SHIP1, SHP-1, and Btk activity. Blood 2003; 102: 558-560.
    CrossrefPubMedGoogle Scholar
  • 63 Bussel JB, Pham LC. Intravenous treatment with gammaglobulin in adults with immune thrombocytopenic purpura: review of the literature. Vox Sang 1987; 52: 206-211.
    CrossrefPubMedGoogle Scholar
  • 64 Godeau B, Lesage S, Divine M. et al. Treatment of adult chronic autoimmune thrombocytopenic purpura with repeated high-dose intravenous immunoglobulin. Blood 1993; 82: 1415-1421.
    PubMedGoogle Scholar
  • 65 Scaradavou A, Woo B, Woloski BM. et al. Intravenous anti-D treatment of immune thrombocytopenic purpura: experience in 272 patients. Blood 1997; 89: 2689-2700.
    PubMedGoogle Scholar
  • 66 Newman GC, Novoa MV, Fodero EM. et al. A dose of 75 microg/kg/d of i.v. anti-D increases the platelet count more rapidly and for a longer period of time than 50 microg/kg/d in adults with immune thrombocytopenic purpura. Br J Haematol 2001; 112: 1076-1078.
    PubMedGoogle Scholar
  • 67 Meyer O, Kiesewetter H, Hermsen M. et al. Replacement of intravenous administration of anti-D by subcutaneous administration in patients with autoimmune thrombocytopenia. Ped Blood Cancer 2006; 47: 721-722.
    CrossrefPubMedGoogle Scholar
  • 68 Bussel JB, Pham LC, Aledort L. et al. Maintenance treatment of adults with chronic refractory immune thrombocytopenic purpura using repeated intravenous infusions of gammaglobulin. Blood 1988; 72: 121-127.
    PubMedGoogle Scholar
  • 69 Cooper N, Woloski BM, Fodero EM. et al. Does treatment with intermittent infusions of intravenous anti-D allow a proportion of adults with recently diagnosed immune thrombocytopenic purpura to avoid splenectomy?. Blood 2002; 99: 1922-1927.
    CrossrefPubMedGoogle Scholar
  • 70 George JN, Raskob GE, Vesely SK. et al. Initial management of immune thrombocytopenic purpura in adults: a randomized controlled trial comparing intermittent anti-D with routine care. Am´J Hematol 2003; 74: 161-169.
    PubMedGoogle Scholar
  • 71 Kattamis AC, Shankar S, Cohen AR. Neurologic complications of treatment of childhood acute immune thrombocytopenic purpura with intravenously administered immunoglobulin G. J Pediatr 1997; 130: 281-283.
    CrossrefPubMedGoogle Scholar
  • 72 Katz U, Achiron A, Sherer Y. et al. Safety of intravenous immunoglobulin (IVIG) therapy. Autoimmunity Rev 2007; 6: 257-259.
    CrossrefPubMedGoogle Scholar
  • 73 Gaines AR. Disseminated intravascular coagulation associated with acute hemoglobinemia or hemoglobinuria following Rh(0)(D) immune globulin intravenous administration for immune thrombocytopenic purpura. Blood 2005; 106: 1532-1537.
    CrossrefPubMedGoogle Scholar
  • 74 British Committee for Standards in Haematology General Haematology Task Force.. Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy. Br J Haematol 2003; 120: 574-596.
    CrossrefPubMedGoogle Scholar
  • 75 Carr JM, Kruskall MS, Kaye JA. et al. Efficacy of platelet transfusions in immune thrombocytopenia. Am J Med 1986; 80: 1051-1054.
    CrossrefPubMedGoogle Scholar
  • 76 Culic S. Recombinant factor VIIa for refractive haemorrhage in autoimmune idiopathic thrombocytopenic purpura. Br J Haematol 2003; 120: 909-910.
    CrossrefPubMedGoogle Scholar
  • 77 Barnes C, Blanchette V, Canning P. et al. Recombinant FVIIa in the management of intracerebral haemorrhage in severe thrombocytopenia unresponsive to platelet-enhancing treatment. Transfus Med 2005; 15: 145-150.
    CrossrefPubMedGoogle Scholar
  • 78 Busani S, Marietta M, Pasetto A. et al. Use of recombinant factor VIIa in a thrombocytopenic patient with spontaneous intracerebral haemorrhage. Thromb Haemost 2005; 93: 381-382.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 79 Savani BN, Dunbar CE, Rick ME. Combination therapy with rFVIIa and platelets for hemorrhage in patients with severe thrombocytopenia and alloimmunization. Am J Hematol 2006; 81: 218-219.
    PubMedGoogle Scholar
  • 80 Wrobel G, Dobaczewski G, Patkowski D. et al. Experiences with recombinant activated factor VII in the treatment of severe refractory thrombocytopenia. Ped Blood Cancer 2006; 47: 729-730.
    CrossrefPubMedGoogle Scholar
  • 81 Kojouri K, Vesely SK, Terrell DR. et al. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood 2004; 104: 2623-2634.
    CrossrefPubMedGoogle Scholar
  • 82 Najean Y, Rain JD, Billotey C. The site of destruction of autologous 111In-labelled platelets and the efficiency of splenectomy in children and adults with idiopathic thrombocytopenic purpura: a study of 578 patients with 268 splenectomies. Br J Haematol 1997; 97: 547-550.
    CrossrefPubMedGoogle Scholar
  • 83 Schilling RF. Estimating the risk for sepsis after splenectomy in hereditary spherocytosis. Ann Intern Med 1995; 122: 187-188.
    CrossrefPubMedGoogle Scholar
  • 84 Davies JM, Barnes R, Milligan D. Update of guidelines for the prevention and treatment of infection in patients with an absent or dysfunctional spleen. Clin Med 2002; 2: 440-443.
    CrossrefPubMedGoogle Scholar
  • 85 Stasi R, Stipa E, Masi M. et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med 1995; 98: 436-442.
    CrossrefPubMedGoogle Scholar
  • 86 Stasi R, Pagano A, Stipa E. et al. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura. Blood 2001; 98: 952-957.
    CrossrefPubMedGoogle Scholar
  • 87 Cooper N, Stasi R, Cunningham-Rundles S. et al. The efficacy and safety of B-cell depletion with anti- CD20 monoclonal antibody in adults with chronic immune thrombocytopenic purpura. Br J Haematol 2004; 125: 232-239.
    CrossrefPubMedGoogle Scholar
  • 88 Arnold DM, Dentali F, Crowther MA. et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med 2007; 146: 25-33.
    CrossrefPubMedGoogle Scholar
  • 89 Godeau B, Fain O, Porcher R. et al. Rituximab Is an Alternative to Splenectomy in Adults with Chronic Immune Thrombocytopenic Purpura: Results of a Multicenter Prospective Phase 2 Study. Blood. 2006 108. Abstract 478.
    PubMedGoogle Scholar
  • 90 Arnal C, Piette JC, Leone J. et al. Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. J Rheumatol 2002; 29: 75-83.
    PubMedGoogle Scholar
  • 91 Galli M, Finazzi G, Barbui T. Thrombocytopenia in the antiphospholipid syndrome. Br J Haematol 1996; 93: 1-5.
    PubMedGoogle Scholar
  • 92 Finazzi G. The Italian Registry of Antiphospholipid Antibodies. Haematologica 1997; 82: 101-105.
    PubMedGoogle Scholar
  • 93 Wang J, Cunningham-Rundles C. Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). J Autoimmun 2005; 25: 57-62.
    CrossrefPubMedGoogle Scholar
  • 94 Michel M, Chanet V, Galicier L. et al. Autoimmune thrombocytopenic purpura and common variable immunodeficiency: analysis of 21 cases and review of the literature. Medicine (Baltimore) 2004; 83: 254-263.
    CrossrefPubMedGoogle Scholar
  • 95 Chang M, Qian JX, Lee SM. et al. Tissue uptake of circulating thrombopoietin is increased in immune-mediated compared with irradiated thrombocytopenic mice. Blood 1999; 93: 2515-2524.
    PubMedGoogle Scholar
  • 96 Kosugi S, Kurata Y, Tomiyama Y. et al. Circulating thrombopoietin level in chronic immune thrombocytopenic purpura. Br J Haematol 1996; 93: 704-706.
    CrossrefPubMedGoogle Scholar
  • 97 Porcelijn L, Folman CC, Bossers B. et al. The diagnostic value of thrombopoietin level measurements in thrombocytopenia. Thromb Haemost 1998; 79: 1101-1105.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 98 Kuter DJ. New thrombopoietic growth factors. Blood 2007; 109: 4607-4616.
    CrossrefPubMedGoogle Scholar
  • 99 Li J, Yang C, Xia Y. et al. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 2001; 98: 3241-3248.
    CrossrefPubMedGoogle Scholar
  • 100 Wang B, Nichol JL, Sullivan JT. Pharmacodynamics and pharmacokinetics of AMG 531, a novel thrombopoietin receptor ligand. Clin Pharm Therapeut 2004; 76: 628-638.
    PubMedGoogle Scholar
  • 101 Bussel JB, Kuter DJ, George JN. et al. AMG 531, a thrombopoiesis-stimulating protein, for chronic ITP. N Engl J Med 2006; 355: 1672-1681.
    CrossrefPubMedGoogle Scholar
  • 102 Newland A, Caulier MT, Kappers-Klunne M. et al. An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura. Br J Haematol 2006; 135: 547-553.
    CrossrefPubMedGoogle Scholar
  • 103 Kuter D, Bussel JB, George J. et al. Long-term dosing of AMG 531 in thrombocytopenic patients with immune thrombocytopenic purpura: 48-week update. Blood. 2006 108. Abstract 476.
    PubMedGoogle Scholar
  • 104 Erickson-Miller CL, DeLorme E, Tian SS. et al. Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist. Exp Hematol 2005; 33: 85-93.
    CrossrefPubMedGoogle Scholar
  • 105 Bussel JB, Cheng G, Saleh M. et al. Analysis of bleeding in patients with immune thrombocytopenic purpura (ITP): a randomized, double-blind, placebocontrolled trial of eltrombopag, an oral platelet growth factor. Blood. 2006 108. Abstract 475.
    PubMedGoogle Scholar
  • 106 Bussel J, Provan A, Shamsi T. et al. Eltrombopag raises platelet count and reduces bleeding compared with placebo during short-term treatment in chronic idiopathic thrombocytopenic purpura: a phase III study. Haematologica 2007; 92 (Suppl. 01) Abstract 1814.
    PubMedGoogle Scholar
  • 107 Desjardins RE, Tempel DL, Lucek R. et al. Single and multiple oral doses of AKR-501 (TM477) increase the platelet count in healthy volunteers. Blood 2006; 108 Abstract 477.
    PubMedGoogle Scholar